Revolutionizing Genomic Research: Helix and Databricks' Innovative Partnership
In a significant move to enhance the realm of genomic research, Helix®, a renowned leader in enterprise genomics, has formed a partnership with Databricks, a prominent player in the data and AI sector. Together, they have unveiled the Helix Research Workspaces, a groundbreaking Trusted Research Environment (TRE) designed to facilitate population-scale clinicogenomic research.
This new initiative is built on the Databricks Data + AI platform, providing approved Helix research partners secure and governed access to a wealth of resources. Specifically, researchers can tap into more than 550,000 GenoSphere™ clinicogenomic records, which merge advanced Exome+® genomic data with over 13 years' worth of electronic health records supplemented by relevant medical and pharmacy claims. This integration aims to streamline the research process, making it not only efficient but also comprehensive.
Population-scale genomic inquiries typically involve considerable technical skill and extensive effort to collate data and create an analysis framework. Such challenges often hinder timely discoveries and limit research participation. The Helix Research Workspaces TRE addresses these issues by presenting data and analysis tools within an intuitive application framework. This allows researchers to spend lesser time setting up infrastructure and focus more on formulating hypotheses, analyzing results, and advancing their findings.
Among its many capabilities, the Research Workspaces TRE features a custom genomic analysis toolkit tailored for population-scale genomic assessments. Additionally, an integrated AI-assisted coding assistant streamlines the process, allowing researchers to compose and enhance their analysis code more efficiently. The platform also hosts collaborative research workspaces, encompassing project-specific notebooks that ensure secure data access and monitoring.
Helix’s CEO, Dr. James Lu, expressed excitement about this collaborative effort, placing emphasis on the transformative potential of integrating data, computational power, and AI instruments. He believes this will expedite scientific advancements, reduce costs, and enhance accessibility for a broader range of researchers, particularly those who previously lacked specialized bioinformatics support. Dr. Lu highlighted the importance of expanding participation in discovery, stating, "Expanding who can participate in discovery is just as important as accelerating the work itself."
Initial results have shown that researchers utilizing the Research Workspaces TRE experienced reduced computing expenditures compared to those working on alternative platforms. The incorporation of AI tools has significantly shortened the time required to derive answers, thus empowering research teams to verify additional hypotheses and validate the integrity of their findings.
Sarah Branfman, Global VP of ISV at Databricks, noted the importance of this collaboration in democratizing access to clinicogenomic research, ultimately contributing to the advancement of precision medicine. She stated, "With Databricks' ISV Built On program, Helix is bringing clinical and genomic data together in a governed and scalable environment, helping research partners accelerate insight, personalize care, and improve patient outcomes."
This latest launch is a part of Helix's ongoing commitment to enhancing research and discovery through a centralized platform, which also includes applications such as partner operations and more. Earlier in the year, Helix introduced the Helix Cohort Builder, enabling researchers to design targeted clinical and genomic cohorts using either a graphical interface or AI-powered natural language search. The establishment of the Trusted Research Environment further builds on these capabilities, enhancing the depth of population analysis.
For those interested in learning more about the Helix Research Workspaces, comprehensive information can be found by visiting helix.com.
In conclusion, the collaboration between Helix and Databricks is fostering a new era in clinicogenomic research, leveraging advanced technology to create a more accessible, efficient, and collaborative research environment. This partnership stands as a testament to the power of innovation in transforming the landscape of precision medicine and genomic studies.
This new initiative is built on the Databricks Data + AI platform, providing approved Helix research partners secure and governed access to a wealth of resources. Specifically, researchers can tap into more than 550,000 GenoSphere™ clinicogenomic records, which merge advanced Exome+® genomic data with over 13 years' worth of electronic health records supplemented by relevant medical and pharmacy claims. This integration aims to streamline the research process, making it not only efficient but also comprehensive.
Population-scale genomic inquiries typically involve considerable technical skill and extensive effort to collate data and create an analysis framework. Such challenges often hinder timely discoveries and limit research participation. The Helix Research Workspaces TRE addresses these issues by presenting data and analysis tools within an intuitive application framework. This allows researchers to spend lesser time setting up infrastructure and focus more on formulating hypotheses, analyzing results, and advancing their findings.
Among its many capabilities, the Research Workspaces TRE features a custom genomic analysis toolkit tailored for population-scale genomic assessments. Additionally, an integrated AI-assisted coding assistant streamlines the process, allowing researchers to compose and enhance their analysis code more efficiently. The platform also hosts collaborative research workspaces, encompassing project-specific notebooks that ensure secure data access and monitoring.
Helix’s CEO, Dr. James Lu, expressed excitement about this collaborative effort, placing emphasis on the transformative potential of integrating data, computational power, and AI instruments. He believes this will expedite scientific advancements, reduce costs, and enhance accessibility for a broader range of researchers, particularly those who previously lacked specialized bioinformatics support. Dr. Lu highlighted the importance of expanding participation in discovery, stating, "Expanding who can participate in discovery is just as important as accelerating the work itself."
Initial results have shown that researchers utilizing the Research Workspaces TRE experienced reduced computing expenditures compared to those working on alternative platforms. The incorporation of AI tools has significantly shortened the time required to derive answers, thus empowering research teams to verify additional hypotheses and validate the integrity of their findings.
Sarah Branfman, Global VP of ISV at Databricks, noted the importance of this collaboration in democratizing access to clinicogenomic research, ultimately contributing to the advancement of precision medicine. She stated, "With Databricks' ISV Built On program, Helix is bringing clinical and genomic data together in a governed and scalable environment, helping research partners accelerate insight, personalize care, and improve patient outcomes."
This latest launch is a part of Helix's ongoing commitment to enhancing research and discovery through a centralized platform, which also includes applications such as partner operations and more. Earlier in the year, Helix introduced the Helix Cohort Builder, enabling researchers to design targeted clinical and genomic cohorts using either a graphical interface or AI-powered natural language search. The establishment of the Trusted Research Environment further builds on these capabilities, enhancing the depth of population analysis.
For those interested in learning more about the Helix Research Workspaces, comprehensive information can be found by visiting helix.com.
In conclusion, the collaboration between Helix and Databricks is fostering a new era in clinicogenomic research, leveraging advanced technology to create a more accessible, efficient, and collaborative research environment. This partnership stands as a testament to the power of innovation in transforming the landscape of precision medicine and genomic studies.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.